PD-1 Antibody, Chidamide, Lenalidomide and Etoposide for Relapsed or Refractory NK/T Cell Lymphoma
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
To observe the safety, tolerability and clinical effects of PD-1 Antibody, Chidamide,
Lenalidomide and Etoposide in Relapsed or Refractory NK/T cell Lymphoma.